Immunosuppressive effects of circulating bile acids in human endotoxemia and septic shock: patients with liver failure are at risk.
Cholestasis
Endotoxemia
Endotoxin tolerance
GPBAR1
Immunosuppression
LPS
Lipopolysaccharide
Monocytes
TGR5
Journal
Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902
Informations de publication
Date de publication:
27 09 2023
27 09 2023
Historique:
received:
16
05
2023
accepted:
18
08
2023
medline:
22
11
2023
pubmed:
28
9
2023
entrez:
27
9
2023
Statut:
epublish
Résumé
Sepsis-induced immunosuppression is a frequent cause of opportunistic infections and death in critically ill patients. A better understanding of the underlying mechanisms is needed to develop targeted therapies. Circulating bile acids with immunosuppressive effects were recently identified in critically ill patients. These bile acids activate the monocyte G-protein coupled receptor TGR5, thereby inducing profound innate immune dysfunction. Whether these mechanisms contribute to immunosuppression and disease severity in sepsis is unknown. The aim of this study was to determine if immunosuppressive bile acids are present in endotoxemia and septic shock and, if so, which patients are particularly at risk. To induce experimental endotoxemia in humans, ten healthy volunteers received 2 ng/kg E. coli lipopolysaccharide (LPS). Circulating bile acids were profiled before and after LPS administration. Furthermore, 48 patients with early (shock onset within < 24 h) and severe septic shock (norepinephrine dose > 0.4 μg/kg/min) and 48 healthy age- and sex-matched controls were analyzed for circulating bile acids. To screen for immunosuppressive effects of circulating bile acids, the capability to induce TGR5 activation was computed for each individual bile acid profile by a recently published formula. Although experimental endotoxemia as well as septic shock led to significant increases in total bile acids compared to controls, this increase was mild in most cases. By contrast, there was a marked and significant increase in circulating bile acids in septic shock patients with severe liver failure compared to healthy controls (61.8 µmol/L vs. 2.8 µmol/L, p = 0.0016). Circulating bile acids in these patients were capable to induce immunosuppression, as indicated by a significant increase in TGR5 activation by circulating bile acids (20.4% in severe liver failure vs. 2.8% in healthy controls, p = 0.0139). Circulating bile acids capable of inducing immunosuppression are present in septic shock patients with severe liver failure. Future studies should examine whether modulation of bile acid metabolism can improve the clinical course and outcome of sepsis in these patients.
Sections du résumé
BACKGROUND
Sepsis-induced immunosuppression is a frequent cause of opportunistic infections and death in critically ill patients. A better understanding of the underlying mechanisms is needed to develop targeted therapies. Circulating bile acids with immunosuppressive effects were recently identified in critically ill patients. These bile acids activate the monocyte G-protein coupled receptor TGR5, thereby inducing profound innate immune dysfunction. Whether these mechanisms contribute to immunosuppression and disease severity in sepsis is unknown. The aim of this study was to determine if immunosuppressive bile acids are present in endotoxemia and septic shock and, if so, which patients are particularly at risk.
METHODS
To induce experimental endotoxemia in humans, ten healthy volunteers received 2 ng/kg E. coli lipopolysaccharide (LPS). Circulating bile acids were profiled before and after LPS administration. Furthermore, 48 patients with early (shock onset within < 24 h) and severe septic shock (norepinephrine dose > 0.4 μg/kg/min) and 48 healthy age- and sex-matched controls were analyzed for circulating bile acids. To screen for immunosuppressive effects of circulating bile acids, the capability to induce TGR5 activation was computed for each individual bile acid profile by a recently published formula.
RESULTS
Although experimental endotoxemia as well as septic shock led to significant increases in total bile acids compared to controls, this increase was mild in most cases. By contrast, there was a marked and significant increase in circulating bile acids in septic shock patients with severe liver failure compared to healthy controls (61.8 µmol/L vs. 2.8 µmol/L, p = 0.0016). Circulating bile acids in these patients were capable to induce immunosuppression, as indicated by a significant increase in TGR5 activation by circulating bile acids (20.4% in severe liver failure vs. 2.8% in healthy controls, p = 0.0139).
CONCLUSIONS
Circulating bile acids capable of inducing immunosuppression are present in septic shock patients with severe liver failure. Future studies should examine whether modulation of bile acid metabolism can improve the clinical course and outcome of sepsis in these patients.
Identifiants
pubmed: 37759239
doi: 10.1186/s13054-023-04620-5
pii: 10.1186/s13054-023-04620-5
pmc: PMC10523742
doi:
Substances chimiques
Bile Acids and Salts
0
Lipopolysaccharides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
372Subventions
Organisme : European Society of Intensive Care Medicine
ID : Levi-Montalcini Biomedical Sciences Award
Organisme : German Federal Ministry of Education and Research
ID : Photonics Research Germany funding program (FKZ: 13N15716)
Organisme : Deutsche Forschungsgemeinschaft
ID : EXC 2051: Balance of the Microverse, project number 390713860
Informations de copyright
© 2023. The Author(s).
Références
Intensive Care Med. 2016 Jan;42(1):16-27
pubmed: 26392257
Clin Sci (Lond). 2017 Apr 25;131(8):747-758
pubmed: 28202686
Cell Metab. 2017 Apr 4;25(4):856-867.e5
pubmed: 28380377
Shock. 2008 Apr;29(4):490-6
pubmed: 17724432
J Pharmacol Exp Ther. 2002 Oct;303(1):273-81
pubmed: 12235261
Crit Care. 2018 Oct 30;22(1):285
pubmed: 30373638
J Clin Apher. 2018 Dec;33(6):638-644
pubmed: 30321466
Crit Care. 2022 May 12;26(1):134
pubmed: 35551628
Front Endocrinol (Lausanne). 2021 May 14;12:681116
pubmed: 34084153
Eur Rev Med Pharmacol Sci. 2021 Mar;25(6):2685-2695
pubmed: 33829455
Gastroenterology. 2005 Sep;129(3):894-901
pubmed: 16143129
J Biol Chem. 2003 Mar 14;278(11):9435-40
pubmed: 12524422
J Hepatol. 2014 Apr;60(4):824-31
pubmed: 24316517
Cell. 2019 Sep 5;178(6):1313-1328.e13
pubmed: 31491384
Nat Rev Immunol. 2013 Dec;13(12):862-74
pubmed: 24232462
JAMA Netw Open. 2019 Feb 1;2(2):e187571
pubmed: 30768188
Crit Care. 2023 Jan 13;27(1):15
pubmed: 36639780
Gut. 1972 Mar;13(3):201-6
pubmed: 5024725
J Clin Invest. 1991 Nov;88(5):1747-54
pubmed: 1939659
PLoS One. 2014 Jun 26;9(6):e100883
pubmed: 24967665
Science. 1999 May 21;284(5418):1362-5
pubmed: 10334992
EMBO Mol Med. 2021 Oct 7;13(10):e14436
pubmed: 34472699
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Toxicol Lett. 2023 Feb 1;374:40-47
pubmed: 36526125
Intensive Care Med. 2013 Aug;39(8):1423-34
pubmed: 23673400
Cell. 2016 Nov 17;167(5):1354-1368.e14
pubmed: 27863248
Gastroenterology. 1999 Feb;116(2):401-10
pubmed: 9922322
Hepatology. 1994 Apr;19(4):882-8
pubmed: 8138261
Microbiome. 2023 Mar 3;11(1):40
pubmed: 36869370
Crit Care Med. 2003 Mar;31(3):834-40
pubmed: 12626993
Gastroenterology. 1997 Jul;113(1):255-64
pubmed: 9207286
Ann Intensive Care. 2017 Dec;7(1):48
pubmed: 28466463
Medicine (Baltimore). 2018 Aug;97(31):e11578
pubmed: 30075526
Crit Care. 2016 Jan 04;20:2
pubmed: 26728364
Gastroenterology. 2002 Apr;122(4):963-73
pubmed: 11910349
Crit Care. 2022 Jun 7;26(1):164
pubmed: 35672834
Intensive Care Med. 2011 Mar;37(3):525-32
pubmed: 21153402
Hepatol Int. 2022 Apr;16(2):396-411
pubmed: 35211843
Crit Care. 2009;13(4):R119
pubmed: 19604380
Biochem Biophys Res Commun. 2002 Nov 15;298(5):714-9
pubmed: 12419312
Am J Respir Crit Care Med. 2009 Oct 1;180(7):640-8
pubmed: 19590022
Semin Immunopathol. 2022 Jul;44(4):547-564
pubmed: 35415765
Intensive Care Med. 2004 Apr;30(4):580-8
pubmed: 14997295
Chest. 2018 Mar;153(3):733-743
pubmed: 28847548
Hepatology. 2003 Oct;38(4):939-46
pubmed: 14512881
Hepatology. 2014 Jul;60(1):202-10
pubmed: 24213952
Lancet Respir Med. 2014 May;2(5):380-6
pubmed: 24740011
Hepatology. 2011 Nov;54(5):1741-52
pubmed: 21800341
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
Clin Chem Lab Med. 2022 Mar 21;60(6):891-900
pubmed: 35313097
J Leukoc Biol. 2013 Dec;94(6):1253-64
pubmed: 23990628
Curr Opin Crit Care. 2022 Apr 1;28(2):216-220
pubmed: 35185139
JAMA. 2014 Jul 2;312(1):90-2
pubmed: 24838355
Crit Care. 2022 Sep 26;26(1):289
pubmed: 36163253
Ann Intensive Care. 2015 May 06;5:9
pubmed: 25992302
Physiol Rev. 2021 Apr 1;101(2):683-731
pubmed: 32790577
PLoS Med. 2012;9(11):e1001338
pubmed: 23152722
Nat Med. 1997 Jun;3(6):678-81
pubmed: 9176497